Probiodrug positioning its pGlu-Abeta Antibody in the field of Abeta antibodies
Probiodrug AG co-authored a review paper on passive Aβ immunotherapy, summarizing current progress and future directions.

Vivoryon Therapeutics is a clinical-stage biotechnology company developing an oral QPCT/L inhibitor for diabetic kidney disease.
vivoryon.comCrawled Nov 15, 2026
Probiodrug AG co-authored a review paper on passive Aβ immunotherapy, summarizing current progress and future directions.
29-30 October 2014
Halle (Saale), Germany // Probiodrug AG, a developer of small molecule inhibitors for the treatment of inflammatory and neurodegenerative diseases, announced today that the United States […]
Vivoryon Therapeutics is a precision medicine company focused on bringing first-in-class therapies to patientssuffering from age-related diseases.
Vivoryon Therapeutics N.V. announces its Q3 2026 financial results and business update. The company is scheduled to release its earnings report on **November 5, 2026**, detailing performance and operational progress. No additional financial or operational specifics are provided in the notice.
Vivoryon Therapeutics N.V. announces the results of its 2026 Annual General Meeting. The company held the meeting on **September 29, 2026**, though specific outcomes or decisions are not detailed in the provided text.
Vivoryon Therapeutics N.V. announces its **H1 2026 financial results and business update** for investor review. The company schedules an **Annual General Meeting** for late September 2026, following the financial disclosure on **August 6, 2026**. No operational or clinical details are provided in the notice.
Vivoryon Therapeutics N.V. announces its Q1 2026 financial results will be released on June 11, 2026. The company provides a business update alongside the earnings report, though no specific details are disclosed in the announcement. Investors and stakeholders await further insights into the company’s performance and strategic direction.
Vivoryon Therapeutics presents new evidence supporting **glutaminyl cyclases** as potential therapeutic targets for **diabetic kidney disease (DKD)** at the **World Congress of Nephrology**. The company highlights a growing body of research validating this approach, positioning it as a promising area for treatment development.
Vivoryon Therapeutics presents Phase 2 clinical trial data on kidney function and biomarkers at the **American Society of Nephrology (ASN) Kidney Week 2025**. The findings focus on evaluating therapeutic interventions for kidney disease, including potential improvements in renal biomarkers and patient outcomes. This presentation highlights progress in Vivoryon’s pipeline of renal therapies, targeting unmet medical needs in nephrology.
Vivoryon Therapeutics N.V. raises **EUR 5.1 million** through a private placement financing round. The company also reports **H1 2025 financial results** and provides business updates, though specific details on performance or strategic shifts are not disclosed in the announcement.